Hepatitis C is primarily to blame for liver cancer, one of the deadliest cancers. In addition, complications of fatty liver disease are also a cause of liver cancer. At present, researchers are tryin...
Research reports published in the Journal of Cancer Epidemiology, Biomarkers, and Prevention show that there is a negative correlation between circulating 25-hydroxyvitamin D [25 (OH) D] levels a...
Nonalcoholic fatty liver disease (NAFLD) is a very common disease. To better understand the link between NAFLD and hepatocellular carcinoma (HCC) risk, researchers at Baylor College of Medicine conduc...
Researchers at the Mayo Clinic in the United States reported at the 2018 Digestive Disease Week meeting that they have developed a DNA blood test that can correctly identify 95% of common liver cancer...
Based on data from the REFLECT phase III trial, the US Food and Drug Administration (FDA) approved Lenvima as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). ...
A research team at the Cancer Research Institute (CSI) of the National University of Singapore has developed a novel peptide drug called FFW that may prevent the development of hepatocellular carcin...
The Swiss Roche Group announced yesterday that TECENTRIQ® (atezolizumab) in combination with Avastin® (bevacizumab) has been approved by the US Food and Drug Administration (FDA) for breakthrough th...
According to a study published in the New England Journal of Medicine published on July 5, Cabozantinib's overall and progression-free survival in patients with advanced hepatocellular carcinoma was s...
Liver cancerLiver cancer is a typical vascular-rich tumor, and tumor blood vessels play a very important role in the development of liver cancer. Therefore, the current targeted therapy of liver cance...
UN NCCN guidelines The US NCCN Clinical Practice Guidelines: Hepatobiliary Tumor (2018.V1) was updated on February 15, 2018. The latest version of the guideline uses proton therapy as one of the stan...